Some additional cytogenetic aberrations in patients treated with Imatinib (STI571)

被引：0
|
作者：
Salamanczuk, Z. [1 ]
Jakobczyk, M. [1 ]
Sacha, T. [1 ]
Skotnicki, A. B. [1 ]
机构：
[1] Jagiellonian Univ, Dept Haematol, PL-31007 Krakow, Poland
来源：
CHROMOSOME RESEARCH | 2005年 / 13卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [21] STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
    Hasserjian, RP
    Boecklin, F
    Parker, S
    Chase, A
    Dhar, S
    Zaiac, M
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 117 (03) : 360 - 367
  • [22] Selective tyrosinekinase inhibitor imatinib (STI571) in haematological and oncological disease
    Hochhaus, A
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (09) : 451 - 456
  • [23] Combination therapy with imatinib mesylate (STI571):: Synopsis of in vitro studies
    Topaly, J
    Zeller, WJ
    Fruehauf, S
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) : 3 - 14
  • [24] Imatinib mesylate (STI571) for myeloid malignancies other than CML
    Krystal, GW
    LEUKEMIA RESEARCH, 2004, 28 : S53 - S59
  • [25] Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
    Renaud Capdeville
    Elisabeth Buchdunger
    Juerg Zimmermann
    Alex Matter
    Nature Reviews Drug Discovery, 2002, 1 : 493 - 502
  • [26] An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells
    Kirk, MJ
    Fotiadis, NA
    Majumdar, SK
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (01) : 49 - 55
  • [27] Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
    Bolton, AE
    Peng, B
    Hubert, M
    Krebs-Brown, A
    Capdeville, R
    Keller, U
    Seiberling, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) : 102 - 106
  • [28] The type of the bcr-abl transcript predicts the cytogenetic responses in chronic myelogenous leukemia patients treated with Glivec(STI571).
    Plouzeau, C
    Petinay, P
    Guilhot, J
    Brizard, F
    Bourmeyster, N
    Kitzis, A
    Brizard, A
    Bertaud, P
    Guilhot, F
    BLOOD, 2001, 98 (11) : 266B - 266B
  • [29] Impact of STI571 (Imatinib) on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
    Rezai, Keyvan
    Lokiec, Francois
    Grandjean, Isabelle
    Weill, Sophie
    de Cremoux, Patricia
    Arnaud, Philippe
    Bordier, Vincent
    Ekue, Richard
    Garcia, Mickael
    Lidereau, Rosette
    Poupon, Marie-France
    Decaudin, Didier
    BLOOD, 2006, 108 (11) : 267B - 267B
  • [30] Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
    Ann E. Bolton
    Bin Peng
    Martine Hubert
    Axel Krebs-Brown
    Renaud Capdeville
    Urs Keller
    Michael Seiberling
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 102 - 106
12345